A Phase 3 interventional study of Filgotinib and Placebo to match filgotinib in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 237 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 8th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Universita di Verona · Sites in Italy
Ages 18–65
R.Bos · Sites in Netherlands
Ages 18–101
Leiden University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,759 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 287 across the 17 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 8 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
12 studies in Arthritis, Rheumatoid by Gilead Sciences: none open now, 1 under way, none of them phase 3. Of 10 finished, 8 (80%) have results posted.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one has the largest enrollment, is one of 6 that started in 2016, is one of 3 in phase 3, and was the 7th registered.
Gilead Sciences’s Arthritis, Rheumatoid studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 12 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX
Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX
Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
Drug: Placebo to match filgotinib · Drug: Adalimumab · Drug: MTX
Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX
Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX
Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX
200 mg or 100 mg tablet(s) administered orally once daily
Also known as: GS-6034
Tablet(s) administered orally once daily
40 mg administered via subcutaneous injection once every two weeks
Administered via subcutaneous injection once every two weeks
Commercially sourced tablet(s) administered orally
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity)participant's pain assessment using VAS on a scale of 0-100 (0 and 100 indicating no pain and unbearable pain) health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions,8 components: dressing/ grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.
Time frame: Week 12
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).
Time frame: Baseline; Week 12
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 12
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP = hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
Time frame: Week 12
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 12
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
Time frame: Week 12
Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
Time frame: Baseline; Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).
Time frame: Baseline; Week 12
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, and 24
ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 2, 4, 12, and 24
Percentage of Participants Who Achieved ACR50 at Weeks 36, and 52
ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 36, and 52
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, and 24
ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 2, 4, 12, and 24
Percentage of Participants Who Achieved ACR70 at Weeks 36, and 52
ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 36, and 52
Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, and 24
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 2, 4, and 24
Percentage of Participants Who Achieved ACR20 Response at Weeks 36, and 52
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 36, and 52
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 2, 4, and 24
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, and 24
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 36, and 52
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, and 24
TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in Individual ACR Component: TJC68 at Weeks 36, and 52
TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 12, and 24
The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in Individual ACR Component: SJC66 at Weeks 36, and 52
The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, and 24
SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in Individual ACR Component: SGA at Weeks 36, and 52
SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 2, 4, 12, and 24
PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in Individual ACR Component: PGA at Weeks 36, and 52
PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 2, 4, 12, and 24
The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 36, and 52
The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 12, and 24
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in Individual ACR Component: hsCRP at Weeks 36, and 52
Time frame: Baseline; Weeks 36, and 52
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, and 24
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 2, 4, 12, and 24
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 36, and 52
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 36, and 52
Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 12, and 24
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in DAS28 (CRP) at Weeks 36, and 52
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 2, 4, and 24
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 2, 4, and 24
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 36, and 52
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 36, and 52
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 2, 4, and 24
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 2, 4, and 24
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 36, and 52
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
Time frame: Weeks 36, and 52
American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 2, 4, 12, and 24
ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.
Time frame: Weeks 2, 4, 12, and 24
ACR N Percent Improvement (ACR-N) at Weeks 36, and 52
ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.
Time frame: Weeks 36, and 52
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 2, 4, 12, and 24
Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.
Time frame: Weeks 2, 4, 12, and 24
Number of Participants With EULAR Response at Weeks 36, and 52
Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.
Time frame: Weeks 36, and 52
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 12, and 24
CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in CDAI at Weeks 36, and 52
CDAI is calculated using formula: CDAI = TJC28 + SJC28 + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 12, and 24
SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 2, 4, 12, and 24
Change From Baseline in SDAI at Weeks 36, and 52
SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in mTSS at Week 52
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).
Time frame: Baseline; Week 52
Percentage of Participants With no Radiographic Progression From Baseline at Week 24
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).
Time frame: Baseline; Weeks 24
Percentage of Participants With no Radiographic Progression From Baseline at Week 52
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).
Time frame: Baseline; Week 52
36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Weeks 4, 12, and 24
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
Time frame: Weeks 4, 12, and 24
SF-36 PCS Score at Weeks 36, and 52
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
Time frame: Weeks 36, and 52
Change From Baseline in SF-36 PCS Score at Weeks 4, and 24
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
Time frame: Baseline; Weeks 4, and 24
Change From Baseline in SF-36 PCS Score at Weeks 36, and 52
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
Time frame: Baseline; Weeks 36, and 52
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
Time frame: Weeks 4, 12, and 24
SF-36 MCS Score at Weeks 36, and 52
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
Time frame: Weeks 36, and 52
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
Time frame: Baseline; Weeks 4, 12, and 24
Change From Baseline in SF-36 MCS Score at Weeks 36, and 52
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
Time frame: Baseline; Weeks 36, and 52
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 4, 12, and 24
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.
Time frame: Weeks 4, 12, and 24
FACIT-Fatigue Score at Weeks 36, and 52
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.
Time frame: Weeks 36, and 52
Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).
Time frame: Baseline; Weeks 4, and 24
Change From Baseline in FACIT-Fatigue Score at Weeks 36, and 52
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).
Time frame: Baseline; Weeks 36, and 52
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
Time frame: Weeks 4, 12, and 24
Number of Participants by EQ-5D Health Profile Categories at Weeks 36, and 52
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
Time frame: Weeks 36, and 52
EQ-5D Current Health VAS at Weeks 4, 12, and 24
EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
Time frame: Weeks 4, 12, and 24
EQ-5D Current Health VAS at Weeks 36, and 52
EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
Time frame: Weeks 36, and 52
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).
Time frame: Baseline; Weeks 4, 12, and 24
Change From Baseline in EQ-5D Current Health VAS at Weeks 36, and 52
The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).
Time frame: Baseline; Weeks 36, and 52
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 4, 12, and 24
WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 36, and 52
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 4, 12, and 24
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 36, and 52
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 4, 12, and 24
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 36, and 52
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 4, 12, and 24
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.
Time frame: Weeks 36, and 52
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 4, 12, and 24
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 4, 12, and 24
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 4, 12, and 24
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 4, 12, and 24
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 36, and 52
Participants were enrolled at study sites in Asia, South Africa, Australia, Europe, North America, South America, and New Zealand. The first participant was screened on 30 August 2016. The last study visit occurred on 20 June 2019.
| Milestone | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg | Placebo Never Received Filgotinib |
|---|---|---|---|---|---|---|
| Started | 477 | 480 | 325 | 190 | 191 | 96 |
| Completed | 424 | 422 | 281 | 181 | 185 | 24 |
| Not completed | 53 | 58 | 44 | 9 | 6 | 72 |
| Withdrew: Withdrew consent | 18 | 29 | 20 | 1 | 2 | 35 |
| Withdrew: Investigator's discretion | 10 | 9 | 10 | 3 | 0 | 15 |
| Withdrew: Adverse event | 17 | 8 | 8 | 4 | 1 | 7 |
| Withdrew: Lost to follow-up | 5 | 7 | 2 | 0 | 2 | 6 |
| Withdrew: Protocol violation | 0 | 1 | 3 | 0 | 0 | 4 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 | 0 | 1 | 2 |
| Withdrew: Death | 1 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but not dosed | 2 | 0 | 0 | 0 | 0 | 2 |
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity)participant's pain assessment using VAS on a scale of 0-100 (0 and 100 indicating no pain and unbearable pain) health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions,8 components: dressing/ grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12 | 76.6 (72.7 to 80.5) | 69.8 (65.6 to 74.0) | 70.5 (65.3 to 75.6) | 49.9 (45.3 to 54.5) |
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 1.59 ± 0.611 | 1.55 ± 0.625 | 1.59 ± 0.600 | 1.63 ± 0.613 |
| Change from Baseline at Week 12 | -0.69 ± 0.613 | -0.56 ± 0.564 | -0.61 ± 0.560 | -0.42 ± 0.544 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP = hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 12 | 34.1 (29.7 to 38.5) | 23.8 (19.8 to 27.7) | 23.7 (18.9 to 28.5) | 9.3 (6.6 to 12.0) |
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 32.47 ± 47.939 | 36.70 ± 53.065 | 34.82 ± 55.013 | 31.60 ± 53.217 |
| Change from Baseline at Week 24 | 0.13 ± 0.937 | 0.17 ± 0.905 | 0.16 ± 0.948 | 0.37 ± 1.417 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 12 | 49.7 (45.1 to 54.3) | 38.8 (34.3 to 43.2) | 43.4 (37.8 to 48.9) | 23.4 (19.5 to 27.3) |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 33.4 ± 7.17 | 33.6 ± 7.75 | 32.8 ± 7.74 | 32.9 ± 7.11 |
| Change from Baseline at Week 12 | 9.2 ± 8.10 | 8.5 ± 7.72 | 8.4 ± 7.89 | 5.8 ± 7.10 |
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 27.6 ± 10.68 | 27.8 ± 10.60 | 27.2 ± 10.20 | 26.9 ± 10.34 |
| Change from Baseline at Week 12 | 9.2 ± 9.82 | 9.1 ± 10.15 | 8.8 ± 9.19 | 6.8 ± 9.89 |
ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 9.1 (6.4 to 11.7) | 5.8 (3.6 to 8.0) | 6.8 (3.9 to 9.7) | 1.1 (0.0 to 2.1) |
| Week 4 | 22.3 (18.5 to 26.2) | 12.9 (9.8 to 16.0) | 17.2 (13.0 to 21.5) | 5.9 (3.7 to 8.1) |
| Week 12 | 47.2 (42.6 to 51.8) | 36.5 (32.0 to 40.9) | 35.1 (29.7 to 40.4) | 19.8 (16.1 to 23.5) |
| Week 24 | 57.9 (53.3 to 62.4) | 52.7 (48.1 to 57.3) | 52.3 (46.7 to 57.9) | 33.3 (28.9 to 37.6) |
ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 63.2 (58.7 to 67.6) | 57.7 (53.2 to 62.2) | 57.5 (52.0 to 63.1) | 67.9 (61.0 to 74.8) | 63.4 (56.3 to 70.4) |
| Week 52 | 64.2 (59.8 to 68.6) | 60.6 (56.2 to 65.1) | 62.2 (56.7 to 67.6) | 68.4 (61.5 to 75.3) | 66.0 (59.0 to 72.9) |
ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 2.7 (1.2 to 4.3) | 1.3 (0.2 to 2.3) | 0.9 (0.0 to 2.1) | 0.4 (0.0 to 1.1) |
| Week 4 | 9.1 (6.4 to 11.7) | 3.3 (1.6 to 5.0) | 3.7 (1.5 to 5.9) | 1.5 (0.3 to 2.7) |
| Week 12 | 26.1 (22.1 to 30.2) | 18.5 (15.0 to 22.1) | 14.2 (10.2 to 18.1) | 6.7 (4.4 to 9.1) |
| Week 24 | 36.2 (31.8 to 40.6) | 29.6 (25.4 to 33.8) | 29.5 (24.4 to 34.7) | 14.9 (11.6 to 18.3) |
ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 40.2 (35.7 to 44.7) | 35.4 (31.0 to 39.8) | 32.9 (27.7 to 38.2) | 44.7 (37.4 to 52.1) | 34.6 (27.5 to 41.6) |
| Week 52 | 44.4 (39.8 to 49.0) | 39.0 (34.5 to 43.4) | 41.2 (35.7 to 46.7) | 48.4 (41.1 to 55.8) | 37.7 (30.6 to 44.8) |
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 37.3 (32.8 to 41.7) | 27.5 (23.4 to 31.6) | 33.5 (28.3 to 38.8) | 14.9 (11.6 to 18.3) |
| Week 4 | 51.6 (47.0 to 56.2) | 45.6 (41.1 to 50.2) | 47.1 (41.5 to 52.7) | 31.8 (27.5 to 36.1) |
| Week 24 | 78.1 (74.3 to 81.9) | 77.7 (73.9 to 81.5) | 74.5 (69.6 to 79.4) | 59.2 (54.6 to 63.7) |
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 82.9 (79.5 to 86.4) | 79.2 (75.4 to 82.9) | 76.3 (71.5 to 81.1) | 90.5 (86.1 to 95.0) | 86.9 (81.9 to 92.0) |
| Week 52 | 82.9 (79.5 to 86.4) | 79.6 (75.9 to 83.3) | 77.8 (73.2 to 82.5) | 86.3 (81.2 to 91.5) | 85.9 (80.7 to 91.1) |
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 1.59 ± 0.611 | 1.55 ± 0.625 | 1.59 ± 0.600 | 1.63 ± 0.613 |
| Change from Baseline at Week 2 | -0.30 ± 0.443 | -0.22 ± 0.406 | -0.29 ± 0.440 | -0.15 ± 0.357 |
| Change from Baseline at Week 4 | -0.43 ± 0.493 | -0.33 ± 0.454 | -0.40 ± 0.460 | -0.26 ± 0.431 |
| Change from Baseline at Week 24 | -0.82 ± 0.632 | -0.75 ± 0.597 | -0.78 ± 0.632 | -0.62 ± 0.598 |
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 1.59 ± 0.611 | 1.55 ± 0.625 | 1.59 ± 0.600 | 1.68 ± 0.578 | 1.58 ± 0.603 |
| Change from Baseline at Week 36 | -0.88 ± 0.633 | -0.80 ± 0.611 | -0.81 ± 0.634 | -0.96 ± 0.637 | -0.69 ± 0.610 |
| Change from Baseline at Week 52 | -0.93 ± 0.649 | -0.85 ± 0.621 | -0.85 ± 0.647 | -0.99 ± 0.644 | -0.73 ± 0.650 |
TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.
| tender joint count | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 25 ± 13.5 | 25 ± 13.4 | 24 ± 13.2 | 24 ± 13.5 |
| Change from Baseline at Week 2 | -8 ± 10.1 | -7 ± 9.3 | -7 ± 8.8 | -5 ± 9.0 |
| Change from Baseline at Week 4 | -11 ± 11.1 | -10 ± 10.3 | -9 ± 9.2 | -8 ± 10.5 |
| Change from Baseline at Week 12 | -17 ± 11.1 | -15 ± 10.7 | -15 ± 9.9 | -13 ± 11.6 |
| Change from Baseline at Week 24 | -20 ± 12.1 | -19 ± 10.9 | -18 ± 11.1 | -17 ± 11.7 |
TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.
| tender joint count | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 25 ± 13.5 | 25 ± 13.4 | 24 ± 13.2 | 25 ± 12.8 | 24 ± 12.9 |
| Change from Baseline at Week 36 | -21 ± 11.9 | -20 ± 11.2 | -19 ± 11.0 | -21 ± 11.4 | -19 ± 11.5 |
| Change from Baseline at Week 52 | -21 ± 12.2 | -21 ± 11.4 | -20 ± 11.4 | -21 ± 11.9 | -20 ± 11.2 |
The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.
| swollen joint count | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 15 ± 8.5 | 15 ± 8.5 | 16 ± 8.4 | 16 ± 8.5 |
| Change from Baseline at Week 2 | -6 ± 6.7 | -5 ± 6.8 | -6 ± 5.8 | -5 ± 6.9 |
| Change from Baseline at Week 4 | -8 ± 7.1 | -8 ± 7.8 | -7 ± 6.6 | -6 ± 7.8 |
| Change from Baseline at Week 12 | -11 ± 7.5 | -11 ± 8.1 | -11 ± 7.1 | -10 ± 8.4 |
| Change from Baseline at Week 24 | -13 ± 7.8 | -13 ± 7.4 | -13 ± 6.9 | -12 ± 7.7 |
The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.
| swollen joint count | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 15 ± 8.5 | 15 ± 8.5 | 16 ± 8.4 | 16 ± 8.2 | 15 ± 7.9 |
| Change from Baseline at Week 36 | -14 ± 7.8 | -13 ± 7.6 | -14 ± 7.1 | -14 ± 7.3 | -13 ± 7.2 |
| Change from Baseline at Week 52 | -14 ± 8.1 | -13 ± 7.6 | -14 ± 7.5 | -14 ± 7.8 | -13 ± 7.4 |
SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 67 ± 19.2 | 65 ± 19.7 | 67 ± 19.1 | 68 ± 18.7 |
| Change from Baseline at Week 2 | -16 ± 20.1 | -11 ± 18.4 | -13 ± 18.1 | -8 ± 17.2 |
| Change from Baseline at Week 4 | -22 ± 21.5 | -16 ± 20.8 | -19 ± 20.8 | -13 ± 20.2 |
| Change from Baseline at Week 12 | -33 ± 24.8 | -28 ± 24.7 | -28 ± 23.2 | -21 ± 24.8 |
| Change from Baseline at Week 24 | -39 ± 25.8 | -36 ± 24.9 | -36 ± 24.9 | -31 ± 26.9 |
SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 67 ± 19.2 | 65 ± 19.7 | 67 ± 19.1 | 70 ± 17.8 | 66 ± 18.7 |
| Change from Baseline at Week 36 | -42 ± 24.2 | -39 ± 25.3 | -39 ± 25.2 | -45 ± 24.7 | -38 ± 25.5 |
| Change from Baseline at Week 52 | -44 ± 24.4 | -41 ± 25.4 | -42 ± 25.7 | -45 ± 27.6 | -41 ± 25.3 |
PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 66 ± 16.0 | 65 ± 16.5 | 67 ± 15.5 | 66 ± 16.2 |
| Change from Baseline at Week 2 | -20 ± 19.3 | -18 ± 18.5 | -19 ± 17.9 | -13 ± 17.8 |
| Change from Baseline at Week 4 | -28 ± 21.2 | -26 ± 19.7 | -26 ± 19.6 | -20 ± 19.6 |
| Change from Baseline at Week 12 | -41 ± 20.2 | -39 ± 20.3 | -39 ± 20.4 | -34 ± 22.4 |
| Change from Baseline at Week 24 | -48 ± 19.2 | -46 ± 19.6 | -47 ± 19.4 | -42 ± 20.4 |
PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 66 ± 16.0 | 65 ± 16.5 | 67 ± 15.5 | 68 ± 15.6 | 64 ± 16.3 |
| Change from Baseline at Week 36 | -51 ± 19.0 | -49 ± 19.8 | -50 ± 18.6 | -53 ± 19.5 | -47 ± 20.0 |
| Change from Baseline at Week 52 | -53 ± 18.2 | -50 ± 19.2 | -52 ± 18.9 | -54 ± 19.7 | -50 ± 19.3 |
The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 65 ± 20.4 | 64 ± 20.1 | 64 ± 19.5 | 66 ± 19.0 |
| Change from Baseline at Week 2 | -16 ± 21.0 | -12 ± 18.7 | -13 ± 20.4 | -7 ± 18.2 |
| Change from Baseline at Week 4 | -21 ± 23.7 | -18 ± 20.9 | -18 ± 21.9 | -12 ± 20.8 |
| Change from Baseline at Week 12 | -31 ± 26.9 | -29 ± 25.3 | -27 ± 23.6 | -21 ± 26.0 |
| Change from Baseline at Week 24 | -38 ± 27.0 | -37 ± 25.6 | -35 ± 24.2 | -30 ± 27.0 |
The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 65 ± 20.4 | 64 ± 20.1 | 64 ± 19.5 | 68 ± 18.0 | 65 ± 19.2 |
| Change from Baseline at Week 36 | -40 ± 26.3 | -38 ± 26.2 | -37 ± 25.5 | -44 ± 24.9 | -39 ± 25.9 |
| Change from Baseline at Week 52 | -43 ± 26.2 | -41 ± 25.9 | -41 ± 25.6 | -45 ± 26.6 | -41 ± 25.6 |
| mg/L | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 16.13 ± 21.005 | 16.74 ± 22.982 | 14.56 ± 18.003 | 16.25 ± 24.051 |
| Change from Baseline at Week 2 | -10.85 ± 20.154 | -7.67 ± 17.888 | -8.03 ± 15.594 | -0.07 ± 17.244 |
| Change from Baseline at Week 4 | -9.99 ± 21.146 | -8.44 ± 20.201 | -7.17 ± 16.896 | -1.12 ± 19.940 |
| Change from Baseline at Week 12 | -11.00 ± 18.659 | -9.55 ± 21.330 | -7.85 ± 20.632 | -3.26 ± 22.711 |
| Change from Baseline at Week 24 | -11.84 ± 20.693 | -10.54 ± 22.215 | -6.17 ± 24.224 | -4.00 ± 19.614 |
| mg/L | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 16.13 ± 21.005 | 16.74 ± 22.982 | 14.56 ± 18.003 | 16.54 ± 24.782 | 15.76 ± 21.871 |
| Change from Baseline at Week 36 | -11.51 ± 21.990 | -10.72 ± 22.569 | -8.73 ± 18.214 | -12.12 ± 23.151 | -8.50 ± 19.749 |
| Change from Baseline at Week 52 | -12.19 ± 20.773 | -11.27 ± 23.129 | -9.60 ± 16.511 | -11.43 ± 20.873 | -8.74 ± 19.921 |
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 52.5 (47.8 to 57.2) | 46.7 (42.0 to 51.3) | 51.9 (46.2 to 57.6) | 40.2 (35.6 to 44.7) |
| Week 4 | 66.2 (61.8 to 70.7) | 58.0 (53.4 to 62.6) | 63.9 (58.5 to 69.4) | 49.9 (45.2 to 54.6) |
| Week 12 | 78.9 (75.0 to 82.7) | 71.5 (67.3 to 75.7) | 72.8 (67.6 to 77.9) | 57.9 (53.3 to 62.5) |
| Week 24 | 76.0 (72.0 to 80.0) | 73.4 (69.3 to 77.6) | 71.2 (66.1 to 76.4) | 59.4 (54.8 to 64.0) |
The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 77.1 (73.2 to 81.1) | 74.9 (70.9 to 79.0) | 71.5 (66.4 to 76.7) | 83.2 (77.6 to 88.9) | 77.7 (71.4 to 83.9) |
| Week 52 | 75.8 (71.8 to 79.8) | 73.0 (68.9 to 77.2) | 70.3 (65.1 to 75.5) | 81.6 (75.8 to 87.5) | 71.8 (65.1 to 78.5) |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 5.8 ± 0.88 | 5.7 ± 0.95 | 5.7 ± 0.88 | 5.7 ± 0.91 |
| Change from Baseline at Week 2 | -1.3 ± 1.05 | -1.0 ± 0.90 | -1.1 ± 0.90 | -0.6 ± 0.79 |
| Change from Baseline at Week 4 | -1.7 ± 1.19 | -1.4 ± 1.07 | -1.4 ± 1.04 | -0.9 ± 0.98 |
| Change from Baseline at Week 12 | -2.5 ± 1.24 | -2.2 ± 1.17 | -2.2 ± 1.12 | -1.6 ± 1.19 |
| Change from Baseline at Week 24 | -3.1 ± 1.17 | -2.8 ± 1.08 | -2.7 ± 1.20 | -2.2 ± 1.20 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 5.8 ± 0.88 | 5.7 ± 0.95 | 5.7 ± 0.88 | 5.9 ± 0.89 | 5.6 ± 0.89 |
| Change from Baseline at Week 36 | -3.2 ± 1.09 | -2.9 ± 1.17 | -2.9 ± 1.16 | -3.3 ± 1.10 | -2.8 ± 1.08 |
| Change from Baseline at Week 52 | -3.4 ± 1.11 | -3.1 ± 1.09 | -3.1 ± 1.13 | -3.3 ± 1.16 | -3.0 ± 1.04 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 13.1 (9.9 to 16.2) | 8.1 (5.6 to 10.7) | 9.8 (6.5 to 13.2) | 3.6 (1.8 to 5.4) |
| Week 4 | 25.5 (21.5 to 29.5) | 20.4 (16.7 to 24.1) | 20.9 (16.3 to 25.5) | 9.3 (6.6 to 12.0) |
| Week 24 | 60.6 (56.1 to 65.1) | 53.1 (48.6 to 57.7) | 50.5 (44.9 to 56.1) | 33.7 (29.3 to 38.0) |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 67.4 (63.0 to 71.7) | 60.2 (55.7 to 64.7) | 58.2 (52.6 to 63.7) | 74.7 (68.3 to 81.2) | 66.5 (59.5 to 73.4) |
| Week 52 | 68.2 (63.9 to 72.5) | 62.1 (57.6 to 66.5) | 61.8 (56.4 to 67.3) | 69.5 (62.7 to 76.3) | 67.5 (60.6 to 74.4) |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 5.1 (3.0 to 7.1) | 1.7 (0.4 to 2.9) | 3.4 (1.3 to 5.5) | 0.6 (0.0 to 1.4) |
| Week 4 | 13.7 (10.5 to 16.9) | 8.8 (6.1 to 11.4) | 8.0 (4.9 to 11.1) | 2.9 (1.3 to 4.6) |
| Week 24 | 48.4 (43.8 to 53.0) | 35.2 (30.8 to 39.6) | 35.7 (30.3 to 41.1) | 16.2 (12.8 to 19.6) |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 50.3 (45.7 to 54.9) | 42.9 (38.4 to 47.4) | 42.5 (36.9 to 48.0) | 52.1 (44.7 to 59.5) | 46.1 (38.7 to 53.4) |
| Week 52 | 54.5 (49.9 to 59.1) | 44.8 (40.2 to 49.3) | 48.6 (43.0 to 54.2) | 50.5 (43.2 to 57.9) | 50.8 (43.4 to 58.1) |
ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.
| percent improvement | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 | 18.3 ± 19.98 | 14.0 ± 17.14 | 16.3 ± 18.41 | 8.0 ± 12.82 |
| Week 4 | 27.4 ± 25.24 | 23.0 ± 22.26 | 23.8 ± 22.94 | 15.1 ± 18.92 |
| Week 12 | 46.8 ± 28.46 | 40.6 ± 27.32 | 40.4 ± 26.18 | 28.1 ± 25.22 |
| Week 24 | 58.8 ± 27.76 | 55.4 ± 26.47 | 54.3 ± 28.13 | 42.6 ± 27.73 |
ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.
| percent improvement | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 62.5 ± 26.01 | 59.1 ± 27.47 | 58.6 ± 27.17 | 63.2 ± 24.59 | 56.1 ± 27.30 |
| Week 52 | 66.0 ± 25.89 | 63.1 ± 26.34 | 63.5 ± 27.03 | 63.8 ± 28.00 | 59.7 ± 26.81 |
Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.
| Participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 2 — Good Response | 58 | 32 | 27 | 15 |
| Week 2 — Moderate Response | 237 | 213 | 158 | 133 |
| Week 2 — No Response | 157 | 219 | 129 | 313 |
| Week 4 — Good Response | 117 | 86 | 61 | 37 |
| Week 4 — Moderate Response | 231 | 242 | 156 | 189 |
| Week 4 — No Response | 115 | 139 | 101 | 228 |
| Week 12 — Good Response | 234 | 177 | 138 | 106 |
| Week 12 — Moderate Response | 188 | 225 | 138 | 224 |
| Week 12 — No Response | 33 | 50 | 32 | 101 |
| Week 24 — Good Response | 284 | 250 | 163 | 154 |
| Week 24 — Moderate Response | 124 | 156 | 97 | 170 |
| Week 24 — No Response | 7 | 13 | 21 | 44 |
Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.
| Participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 — Good Response | 306 | 276 | 180 | 139 | 124 |
| Week 36 — Moderate Response | 99 | 126 | 84 | 38 | 54 |
| Week 36 — No Response | 2 | 11 | 8 | 0 | 6 |
| Week 52 — Good Response | 308 | 282 | 189 | 129 | 126 |
| Week 52 — Moderate Response | 82 | 98 | 66 | 38 | 42 |
| Week 52 — No Response | 3 | 5 | 4 | 2 | 3 |
CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 39.5 ± 11.85 | 38.6 ± 12.23 | 39.2 ± 11.51 | 39.6 ± 11.66 |
| Change from Baseline at Week 2 | -12.7 ± 11.86 | -10.7 ± 11.17 | -11.7 ± 10.06 | -8.2 ± 10.10 |
| Change from Baseline at Week 4 | -17.6 ± 12.66 | -15.6 ± 12.07 | -15.4 ± 11.13 | -12.4 ± 11.79 |
| Change from Baseline at Week 12 | -26.0 ± 12.41 | -23.3 ± 12.32 | -23.5 ± 11.43 | -20.3 ± 13.30 |
| Change from Baseline at Week 24 | -30.6 ± 11.88 | -28.6 ± 11.57 | -28.4 ± 11.45 | -26.3 ± 12.38 |
CDAI is calculated using formula: CDAI = TJC28 + SJC28 + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 39.5 ± 11.85 | 38.6 ± 12.23 | 39.2 ± 11.51 | 41.4 ± 11.03 | 37.8 ± 11.23 |
| Change from Baseline at Week 36 | -32.1 ± 11.60 | -29.9 ± 12.18 | -30.4 ± 11.21 | -33.8 ± 11.15 | -29.0 ± 11.02 |
| Change from Baseline at Week 52 | -32.9 ± 11.69 | -30.9 ± 11.70 | -31.6 ± 11.44 | -34.0 ± 11.20 | -30.7 ± 10.80 |
SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 41.2 ± 12.26 | 40.2 ± 12.79 | 40.6 ± 11.88 | 41.2 ± 12.37 |
| Change from Baseline at Week 2 | -14.0 ± 12.19 | -11.4 ± 11.41 | -12.5 ± 10.52 | -8.2 ± 10.38 |
| Change from Baseline at Week 4 | -18.6 ± 13.08 | -16.4 ± 12.31 | -16.1 ± 11.47 | -12.5 ± 12.18 |
| Change from Baseline at Week 12 | -27.1 ± 12.69 | -24.1 ± 12.54 | -24.3 ± 12.03 | -20.6 ± 13.85 |
| Change from Baseline at Week 24 | -31.8 ± 12.18 | -29.7 ± 12.01 | -29.0 ± 12.19 | -26.6 ± 12.91 |
SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 41.2 ± 12.26 | 40.2 ± 12.79 | 40.6 ± 11.88 | 43.0 ± 11.81 | 39.4 ± 11.81 |
| Change from Baseline at Week 36 | -33.3 ± 11.92 | -31.0 ± 12.69 | -31.2 ± 11.73 | -35.1 ± 11.83 | -29.9 ± 11.40 |
| Change from Baseline at Week 52 | -34.1 ± 12.15 | -32.0 ± 12.25 | -32.6 ± 11.99 | -34.9 ± 11.83 | -31.6 ± 11.11 |
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 32.62 ± 48.306 | 36.24 ± 52.956 | 33.94 ± 53.803 | 26.68 ± 45.870 | 32.38 ± 55.012 |
| Change from Baseline at Week 52 | 0.21 ± 1.434 | 0.50 ± 2.098 | 0.58 ± 3.621 | 0.63 ± 2.782 | 0.90 ± 3.152 |
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Change in mTSS ≤ 0.5 | 93.8 (91.4 to 96.3) | 91.1 (88.2 to 94.0) | 91.9 (88.4 to 95.3) | 87.2 (83.5 to 90.8) |
| Change in mTSS ≤ 0 | 87.9 (84.6 to 91.2) | 85.9 (82.4 to 89.4) | 86.3 (82.1 to 90.6) | 80.9 (76.7 to 85.2) |
| Change in mTSS ≤ SDC (1.36) | 95.8 (93.7 to 97.9) | 95.0 (92.8 to 97.3) | 94.5 (91.6 to 97.4) | 90.3 (87.1 to 93.6) |
Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Change in mTSS ≤ 0.5 | 92.1 (89.4 to 94.8) | 87.1 (83.7 to 90.5) | 88.6 (84.7 to 92.6) | 83.9 (78.2 to 89.5) | 83.7 (78.0 to 89.4) |
| Change in mTSS ≤ 0 | 87.5 (84.2 to 90.8) | 81.3 (77.4 to 85.2) | 82.4 (77.7 to 87.1) | 73.3 (66.6 to 80.1) | 77.0 (70.5 to 83.4) |
| Change in mTSS ≤ SDC (1.83) | 95.0 (92.7 to 97.2) | 91.5 (88.7 to 94.3) | 94.1 (91.2 to 97.1) | 90.0 (85.3 to 94.7) | 87.6 (82.5 to 92.8) |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 39.0 ± 8.22 | 38.2 ± 8.35 | 37.7 ± 8.07 | 36.1 ± 7.40 |
| Week 12 | 42.7 ± 8.30 | 42.1 ± 8.69 | 41.3 ± 8.57 | 38.8 ± 7.83 |
| Week 24 | 43.9 ± 8.49 | 43.7 ± 8.64 | 43.2 ± 8.95 | 40.7 ± 8.10 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 45.2 ± 8.28 | 44.4 ± 8.54 | 43.8 ± 8.84 | 45.2 ± 7.99 | 43.2 ± 8.82 |
| Week 52 | 45.6 ± 8.35 | 45.1 ± 8.57 | 45.2 ± 8.55 | 45.1 ± 8.26 | 44.1 ± 8.88 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 33.4 ± 7.17 | 33.6 ± 7.75 | 32.8 ± 7.74 | 32.9 ± 7.11 |
| Change from Baseline at Week 4 | 5.6 ± 6.57 | 4.6 ± 6.50 | 5.0 ± 6.65 | 3.1 ± 6.32 |
| Change from Baseline at Week 24 | 10.4 ± 8.49 | 10.3 ± 8.64 | 10.4 ± 8.47 | 7.7 ± 7.97 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 33.4 ± 7.17 | 33.6 ± 7.75 | 32.8 ± 7.74 | 32.2 ± 6.96 | 33.7 ± 6.96 |
| Change from Baseline at Week 36 | 11.6 ± 8.28 | 11.0 ± 8.53 | 11.1 ± 9.07 | 12.9 ± 8.92 | 9.5 ± 8.13 |
| Change from Baseline at Week 52 | 12.0 ± 8.73 | 11.5 ± 8.74 | 12.4 ± 9.21 | 13.0 ± 9.58 | 10.4 ± 8.05 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 47.8 ± 9.90 | 47.9 ± 9.63 | 47.9 ± 10.04 | 45.8 ± 10.35 |
| Week 12 | 49.3 ± 9.14 | 49.9 ± 8.90 | 48.9 ± 10.28 | 47.7 ± 10.16 |
| Week 24 | 50.0 ± 8.82 | 50.2 ± 8.93 | 49.3 ± 10.26 | 49.2 ± 9.90 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 50.1 ± 8.96 | 51.3 ± 8.88 | 50.7 ± 9.67 | 50.7 ± 9.04 | 50.3 ± 9.47 |
| Week 52 | 50.6 ± 9.30 | 51.5 ± 8.99 | 50.8 ± 9.51 | 50.8 ± 8.55 | 50.1 ± 9.21 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 43.9 ± 10.44 | 44.6 ± 10.44 | 44.1 ± 10.44 | 43.4 ± 11.01 |
| Change from Baseline at Week 4 | 3.9 ± 7.96 | 3.4 ± 8.35 | 3.7 ± 7.66 | 2.3 ± 8.72 |
| Change from Baseline at Week 12 | 5.4 ± 9.45 | 5.4 ± 8.97 | 4.9 ± 9.69 | 4.1 ± 9.50 |
| Change from Baseline at Week 24 | 6.1 ± 9.23 | 5.7 ± 9.57 | 5.3 ± 9.25 | 5.6 ± 10.28 |
The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 43.9 ± 10.44 | 44.6 ± 10.44 | 44.1 ± 10.44 | 43.9 ± 11.06 | 43.4 ± 11.03 |
| Change from Baseline at Week 36 | 6.2 ± 10.03 | 6.6 ± 10.46 | 6.6 ± 9.40 | 6.9 ± 12.05 | 6.8 ± 9.84 |
| Change from Baseline at Week 52 | 6.7 ± 10.53 | 6.9 ± 10.61 | 6.7 ± 9.90 | 7.2 ± 11.31 | 6.5 ± 10.35 |
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 33.9 ± 10.32 | 33.3 ± 9.76 | 32.9 ± 10.11 | 30.9 ± 10.43 |
| Week 12 | 36.8 ± 9.64 | 36.7 ± 9.67 | 36.1 ± 9.68 | 33.9 ± 10.32 |
| Week 24 | 38.5 ± 9.17 | 38.5 ± 8.74 | 37.6 ± 9.82 | 35.8 ± 9.94 |
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 38.9 ± 8.84 | 39.5 ± 8.73 | 38.6 ± 9.45 | 39.6 ± 8.78 | 37.4 ± 9.88 |
| Week 52 | 39.8 ± 8.64 | 39.8 ± 8.54 | 38.9 ± 9.87 | 39.4 ± 8.78 | 38.0 ± 9.77 |
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 27.6 ± 10.68 | 27.8 ± 10.60 | 27.2 ± 10.20 | 26.9 ± 10.34 |
| Change from Baseline at Week 4 | 6.3 ± 8.59 | 5.7 ± 8.77 | 5.7 ± 8.47 | 3.8 ± 8.76 |
| Change from Baseline at Week 24 | 10.5 ± 10.63 | 10.8 ± 10.77 | 10.3 ± 9.67 | 8.4 ± 10.48 |
FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 27.6 ± 10.68 | 27.8 ± 10.60 | 27.2 ± 10.20 | 26.8 ± 10.13 | 27.9 ± 10.56 |
| Change from Baseline at Week 36 | 11.0 ± 10.22 | 11.7 ± 10.90 | 11.3 ± 10.18 | 12.8 ± 10.76 | 9.5 ± 10.25 |
| Change from Baseline at Week 52 | 11.9 ± 10.21 | 12.2 ± 10.88 | 11.7 ± 10.79 | 12.9 ± 11.55 | 10.1 ± 10.06 |
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
| Participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Mobility: Week 4 — No Problems | 130 | 129 | 84 | 100 |
| Mobility: Week 4 — Slight Problems | 176 | 173 | 107 | 149 |
| Mobility: Week 4 — Moderate Problems | 113 | 122 | 96 | 150 |
| Mobility: Week 4 — Severe Problems | 44 | 46 | 31 | 56 |
| Mobility: Week 4 — Extreme Problems | 5 | 1 | 1 | 2 |
| Mobility: Week 12 — No Problems | 178 | 177 | 116 | 132 |
| Mobility: Week 12 — Slight Problems | 153 | 151 | 103 | 154 |
| Mobility: Week 12 — Moderate Problems | 99 | 97 | 67 | 112 |
| Mobility: Week 12 — Severe Problems | 21 | 31 | 21 | 38 |
| Mobility: Week 12 — Extreme Problems | 4 | 1 | 0 | 1 |
| Mobility: week 24 — No Problems | 182 | 189 | 117 | 131 |
| Mobility: week 24 — Slight Problems | 142 | 136 | 90 | 126 |
| Mobility: week 24 — Moderate Problems | 68 | 75 | 57 | 89 |
| Mobility: week 24 — Severe Problems | 19 | 17 | 12 | 24 |
| Mobility: week 24 — Extreme Problems | 5 | 2 | 1 | 2 |
| Self-care: Week 4 — No Problems | 177 | 163 | 111 | 138 |
| Self-care: Week 4 — Slight Problems | 180 | 183 | 120 | 164 |
| Self-care: Week 4 — Moderate Problems | 86 | 103 | 74 | 124 |
| Self-care: Week 4 — Severe Problems | 23 | 20 | 13 | 25 |
| Self-care: Week 4 — Extreme Problems | 2 | 2 | 1 | 6 |
| Self-care: Week 12 — No Problems | 243 | 222 | 147 | 165 |
| Self-care: Week 12 — Slight Problems | 149 | 150 | 102 | 159 |
| Self-care: Week 12 — Moderate Problems | 53 | 74 | 49 | 88 |
| Self-care: Week 12 — Severe Problems | 8 | 9 | 9 | 21 |
| Self-care: Week 12 — Extreme Problems | 2 | 2 | 0 | 4 |
| Self-care: Week 24 — No Problems | 255 | 249 | 157 | 164 |
| Self-care: Week 24 — Slight Problems | 109 | 121 | 75 | 140 |
| Self-care: Week 24 — Moderate Problems | 45 | 39 | 36 | 54 |
| Self-care: Week 24 — Severe Problems | 4 | 8 | 7 | 14 |
| Self-care: Week 24 — Extreme Problems | 3 | 2 | 2 | 0 |
| Usual Activities: Week 4 — No Problems | 110 | 102 | 69 | 65 |
| Usual Activities: Week 4 — Slight Problems | 203 | 193 | 133 | 195 |
| Usual Activities: Week 4 — Moderate Problems | 111 | 142 | 90 | 143 |
| Usual Activities: Week 4 — Severe Problems | 38 | 33 | 25 | 52 |
| Usual Activities: Week 4 — Extreme Problems | 6 | 1 | 2 | 2 |
| Usual Activities: Week 12 — No Problems | 157 | 149 | 97 | 103 |
| Usual Activities: Week 12 — Slight Problems | 200 | 191 | 130 | 184 |
| Usual Activities: Week 12 — Moderate Problems | 80 | 90 | 67 | 116 |
| Usual Activities: Week 12 — Severe Problems | 16 | 23 | 13 | 32 |
| Usual Activities: Week 12 — Extreme Problems | 2 | 4 | 0 | 2 |
| Usual Activities: Week 24 — No Problems | 184 | 175 | 109 | 107 |
| Usual Activities: Week 24 — Slight Problems | 164 | 171 | 105 | 163 |
| Usual Activities: Week 24 — Moderate Problems | 54 | 63 | 52 | 86 |
| Usual Activities: Week 24 — Severe Problems | 13 | 9 | 9 | 15 |
| Usual Activities: Week 24 — Extreme Problems | 1 | 1 | 2 | 1 |
| Pain/Discomfort: Week 4 — No Problems | 42 | 38 | 26 | 14 |
| Pain/Discomfort: Week 4 — Slight Problems | 215 | 185 | 118 | 157 |
| Pain/Discomfort: Week 4 — Moderate Problems | 154 | 204 | 127 | 198 |
| Pain/Discomfort: Week 4 — Severe Problems | 51 | 41 | 47 | 80 |
| Pain/Discomfort: Week 4 — Extreme Problems | 6 | 3 | 1 | 8 |
| Pain/Discomfort: Week 12 — No Problems | 58 | 71 | 34 | 29 |
| Pain/Discomfort: Week 12 — Slight Problems | 260 | 217 | 145 | 200 |
| Pain/Discomfort: Week 12 — Moderate Problems | 117 | 150 | 106 | 154 |
| Pain/Discomfort: Week 12 — Severe Problems | 20 | 17 | 22 | 51 |
| Pain/Discomfort: Week 12 — Extreme Problems | 0 | 2 | 0 | 3 |
| Pain/Discomfort: Week 24 — No Problems | 82 | 78 | 56 | 39 |
| Pain/Discomfort: Week 24 — Slight Problems | 226 | 224 | 127 | 196 |
| Pain/Discomfort: Week 24 — Moderate Problems | 86 | 103 | 82 | 110 |
| Pain/Discomfort: Week 24 — Severe Problems | 21 | 13 | 12 | 27 |
| Pain/Discomfort: Week 24 — Extreme Problems | 1 | 1 | 0 | 0 |
| Anxiety/Depression: Week 4 — No Problems | 211 | 224 | 151 | 196 |
| Anxiety/Depression: Week 4 — Slight Problems | 163 | 158 | 111 | 149 |
| Anxiety/Depression: Week 4 — Moderate Problems | 72 | 81 | 44 | 86 |
| Anxiety/Depression: Week 4 — Severe Problems | 21 | 8 | 13 | 25 |
| Anxiety/Depression: Week 4 — Extreme Problems | 1 | 0 | 0 | 1 |
| Anxiety/Depression: Week 12 — No Problems | 235 | 246 | 152 | 216 |
| Anxiety/Depression: Week 12 — Slight Problems | 154 | 143 | 106 | 137 |
| Anxiety/Depression: Week 12 — Moderate Problems | 54 | 63 | 44 | 62 |
| Anxiety/Depression: Week 12 — Severe Problems | 12 | 5 | 4 | 19 |
| Anxiety/Depression: Week 12 — Extreme Problems | 0 | 0 | 1 | 3 |
| Anxiety/Depression: Week 24 — No Problems | 230 | 256 | 160 | 204 |
| Anxiety/Depression: Week 24 — Slight Problems | 136 | 119 | 75 | 120 |
| Anxiety/Depression: Week 24 — Moderate Problems | 42 | 37 | 33 | 39 |
| Anxiety/Depression: Week 24 — Severe Problems | 8 | 5 | 6 | 8 |
| Anxiety/Depression: Week 24 — Extreme Problems | 0 | 2 | 3 | 1 |
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
| Participants | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Mobility: Week 36 — No Problems | 202 | 189 | 122 | 86 | 78 |
| Mobility: Week 36 — Slight Problems | 121 | 136 | 82 | 58 | 67 |
| Mobility: Week 36 — Moderate Problems | 58 | 64 | 48 | 26 | 28 |
| Mobility: Week 36 — Severe Problems | 13 | 15 | 16 | 7 | 11 |
| Mobility: Week 36 — Extreme Problems | 1 | 1 | 2 | 0 | 0 |
| Mobility: Week 52 — No Problems | 197 | 187 | 130 | 82 | 77 |
| Mobility: Week 52 — Slight Problems | 117 | 115 | 79 | 47 | 61 |
| Mobility: Week 52 — Moderate Problems | 57 | 58 | 38 | 34 | 27 |
| Mobility: Week 52 — Severe Problems | 11 | 19 | 10 | 3 | 8 |
| Mobility: Week 52 — Extreme Problems | 4 | 0 | 0 | 1 | 1 |
| Self-care: Week 36 — No Problems | 254 | 249 | 164 | 114 | 108 |
| Self-care: Week 36 — Slight Problems | 104 | 113 | 67 | 45 | 46 |
| Self-care: Week 36 — Moderate Problems | 31 | 36 | 30 | 17 | 25 |
| Self-care: Week 36 — Severe Problems | 5 | 5 | 6 | 1 | 5 |
| Self-care: Week 36 — Extreme Problems | 1 | 2 | 3 | 0 | 0 |
| Self-care: Week 52 — No Problems | 251 | 245 | 159 | 105 | 101 |
| Self-care: Week 52 — Slight Problems | 98 | 102 | 72 | 44 | 48 |
| Self-care: Week 52 — Moderate Problems | 30 | 25 | 24 | 16 | 18 |
| Self-care: Week 52 — Severe Problems | 5 | 6 | 2 | 1 | 6 |
| Self-care: Week 52 — Extreme Problems | 2 | 1 | 0 | 1 | 1 |
| Usual Activities: Week 36 — No Problems | 176 | 172 | 125 | 82 | 72 |
| Usual Activities: Week 36 — Slight Problems | 160 | 171 | 90 | 71 | 70 |
| Usual Activities: Week 36 — Moderate Problems | 50 | 52 | 46 | 21 | 36 |
| Usual Activities: Week 36 — Severe Problems | 7 | 9 | 7 | 3 | 5 |
| Usual Activities: Week 36 — Extreme Problems | 2 | 1 | 2 | 0 | 1 |
| Usual Activities: Week 52 — No Problems | 183 | 177 | 121 | 75 | 71 |
| Usual Activities: Week 52 — Slight Problems | 151 | 147 | 87 | 64 | 72 |
| Usual Activities: Week 52 — Moderate Problems | 40 | 41 | 42 | 22 | 19 |
| Usual Activities: Week 52 — Severe Problems | 8 | 12 | 6 | 5 | 12 |
| Usual Activities: Week 52 — Extreme Problems | 4 | 2 | 1 | 1 | 0 |
| Pain/Discomfort: Week 36 — No Problems | 95 | 84 | 55 | 47 | 35 |
| Pain/Discomfort: Week 36 — Slight Problems | 206 | 220 | 127 | 94 | 97 |
| Pain/Discomfort: Week 36 — Moderate Problems | 81 | 89 | 79 | 34 | 45 |
| Pain/Discomfort: Week 36 — Severe Problems | 13 | 11 | 8 | 2 | 7 |
| Pain/Discomfort: Week 36 — Extreme Problems | 0 | 1 | 1 | 0 | 0 |
| Pain/Discomfort: Week 52 — No Problems | 90 | 88 | 57 | 45 | 44 |
| Pain/Discomfort: Week 52 — Slight Problems | 209 | 210 | 130 | 80 | 93 |
| Pain/Discomfort: Week 52 — Moderate Problems | 77 | 72 | 61 | 38 | 31 |
| Pain/Discomfort: Week 52 — Severe Problems | 10 | 9 | 9 | 3 | 6 |
| Pain/Discomfort: Week 52 — Extreme Problems | 0 | 0 | 0 | 1 | 0 |
| Anxiety/Depression: Week 36 — No Problems | 230 | 259 | 162 | 115 | 112 |
| Anxiety/Depression: Week 36 — Slight Problems | 123 | 113 | 79 | 44 | 51 |
| Anxiety/Depression: Week 36 — Moderate Problems | 37 | 27 | 19 | 18 | 16 |
| Anxiety/Depression: Week 36 — Severe Problems | 4 | 5 | 7 | 0 | 5 |
| Anxiety/Depression: Week 36 — Extreme Problems | 1 | 1 | 3 | 0 | 0 |
| Anxiety/Depression: Week 52 — No Problems | 227 | 254 | 169 | 111 | 110 |
| Anxiety/Depression: Week 52 — Slight Problems | 106 | 86 | 61 | 38 | 41 |
| Anxiety/Depression: Week 52 — Moderate Problems | 48 | 34 | 23 | 17 | 19 |
| Anxiety/Depression: Week 52 — Severe Problems | 5 | 5 | 4 | 0 | 4 |
| Anxiety/Depression: Week 52 — Extreme Problems | 0 | 0 | 0 | 1 | 0 |
EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 59 ± 20.5 | 59 ± 19.9 | 60 ± 20.4 | 56 ± 19.5 |
| Week 12 | 66 ± 20.3 | 66 ± 20.3 | 65 ± 19.6 | 59 ± 20.7 |
| Week 24 | 67 ± 23.1 | 69 ± 21.6 | 68 ± 22.2 | 64 ± 21.4 |
EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 69 ± 22.7 | 72 ± 21.2 | 67 ± 24.3 | 73 ± 19.9 | 71 ± 21.1 |
| Week 52 | 72 ± 21.3 | 73 ± 21.0 | 71 ± 22.5 | 73 ± 20.6 | 70 ± 22.8 |
The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 48 ± 22.5 | 49 ± 22.8 | 47 ± 21.8 | 46 ± 21.8 |
| Change from Baseline at Week 4 | 11 ± 24.4 | 10 ± 25.2 | 13 ± 24.4 | 10 ± 25.1 |
| Change from Baseline at Week 12 | 18 ± 26.3 | 17 ± 27.4 | 17 ± 27.1 | 13 ± 26.5 |
| Change from Baseline at Week 24 | 19 ± 30.5 | 21 ± 28.9 | 21 ± 28.8 | 18 ± 29.3 |
The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).
| score on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 48 ± 22.5 | 49 ± 22.8 | 47 ± 21.8 | 45 ± 21.6 | 47 ± 21.1 |
| Change from Baseline at Week 36 | 21 ± 30.6 | 23 ± 28.5 | 20 ± 30.9 | 28 ± 28.2 | 24 ± 26.0 |
| Change from Baseline at Week 52 | 25 ± 29.3 | 24 ± 28.5 | 24 ± 29.2 | 29 ± 28.6 | 23 ± 29.6 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.
| percentage of work time missed | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 8.5 ± 21.27 | 6.6 ± 16.47 | 9.2 ± 21.99 | 9.4 ± 21.41 |
| Week 12 | 6.6 ± 17.06 | 5.4 ± 14.56 | 7.1 ± 18.46 | 9.5 ± 22.66 |
| Week 24 | 4.4 ± 13.54 | 3.6 ± 10.24 | 7.2 ± 17.72 | 10.5 ± 21.86 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.
| percentage of work time missed | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 5.5 ± 16.17 | 7.7 ± 19.46 | 7.0 ± 19.65 | 6.8 ± 19.79 | 8.4 ± 19.97 |
| Week 52 | 4.8 ± 14.39 | 5.4 ± 15.10 | 7.4 ± 20.12 | 5.5 ± 13.24 | 5.8 ± 14.29 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.
| percentage of impairment while working | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 34.3 ± 22.69 | 36.9 ± 24.01 | 35.6 ± 22.39 | 42.5 ± 23.54 |
| Week 12 | 26.3 ± 21.07 | 26.9 ± 22.57 | 27.6 ± 21.51 | 34.0 ± 21.98 |
| Week 24 | 22.0 ± 21.28 | 21.0 ± 20.74 | 25.7 ± 21.99 | 30.9 ± 23.11 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.
| percentage of impairment while working | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 20.2 ± 19.54 | 19.6 ± 20.27 | 21.2 ± 20.74 | 21.5 ± 18.72 | 25.8 ± 23.51 |
| Week 52 | 18.2 ± 18.83 | 17.3 ± 19.25 | 20.8 ± 21.78 | 22.3 ± 21.82 | 19.5 ± 20.04 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.
| percentage of work productivity loss | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 37.0 ± 24.64 | 39.5 ± 25.17 | 38.4 ± 24.59 | 45.1 ± 25.18 |
| Week 12 | 29.5 ± 24.25 | 29.3 ± 24.73 | 30.7 ± 24.34 | 36.7 ± 24.27 |
| Week 24 | 24.4 ± 23.06 | 23.2 ± 22.64 | 29.1 ± 23.88 | 34.9 ± 26.04 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.
| percentage of work productivity loss | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 23.3 ± 22.02 | 23.9 ± 23.98 | 23.8 ± 22.95 | 24.0 ± 21.33 | 29.1 ± 26.79 |
| Week 52 | 20.6 ± 21.74 | 20.5 ± 22.15 | 24.3 ± 24.77 | 25.7 ± 24.32 | 22.3 ± 24.10 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.
| percentage of activity impairment | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Week 4 | 44.6 ± 24.18 | 46.2 ± 24.05 | 46.4 ± 23.84 | 52.1 ± 23.41 |
| Week 12 | 35.1 ± 23.86 | 36.6 ± 24.51 | 38.3 ± 25.57 | 44.3 ± 23.73 |
| Week 24 | 30.2 ± 24.69 | 30.4 ± 23.07 | 32.5 ± 24.40 | 39.3 ± 23.69 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.
| percentage of activity impairment | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Week 36 | 28.3 ± 23.30 | 28.7 ± 23.47 | 31.3 ± 25.44 | 28.3 ± 22.47 | 32.3 ± 23.62 |
| Week 52 | 26.0 ± 22.44 | 26.3 ± 22.71 | 28.1 ± 24.38 | 28.6 ± 23.57 | 28.9 ± 23.07 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of work time missed | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 12.0 ± 25.77 | 9.9 ± 20.91 | 16.0 ± 27.57 | 17.0 ± 29.52 |
| Change from Baseline at Week 4 | -1.4 ± 21.24 | -2.1 ± 18.14 | -7.5 ± 24.26 | -5.7 ± 25.65 |
| Change from Baseline at Week 12 | -4.3 ± 22.55 | -3.8 ± 18.37 | -7.5 ± 28.79 | -5.9 ± 27.94 |
| Change from Baseline at Week 24 | -6.1 ± 24.77 | -3.8 ± 16.92 | -9.3 ± 28.99 | -1.5 ± 27.24 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of work time missed | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 12.0 ± 25.77 | 9.9 ± 20.91 | 16.0 ± 27.57 | 18.3 ± 31.61 | 14.6 ± 26.88 |
| Change from Baseline at Week 36 | -4.4 ± 24.04 | -1.5 ± 24.41 | -8.7 ± 27.43 | -6.2 ± 30.25 | -7.5 ± 25.00 |
| Change from Baseline at Week 52 | -6.8 ± 26.27 | -1.7 ± 21.89 | -7.1 ± 24.00 | -7.4 ± 26.76 | -8.9 ± 27.90 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of impairment while working | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 49.1 ± 25.23 | 48.0 ± 24.61 | 50.8 ± 22.98 | 52.5 ± 25.89 |
| Change from Baseline at Week 4 | -15.1 ± 23.19 | -10.2 ± 22.82 | -15.3 ± 24.84 | -9.5 ± 23.68 |
| Change from Baseline at Week 12 | -24.1 ± 25.83 | -21.9 ± 23.22 | -22.9 ± 24.88 | -17.1 ± 27.24 |
| Change from Baseline at Week 24 | -27.4 ± 26.37 | -25.9 ± 26.59 | -23.3 ± 27.56 | -21.2 ± 29.33 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of impairment while working | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 49.1 ± 25.23 | 48.0 ± 24.61 | 50.8 ± 22.98 | 53.8 ± 26.35 | 53.6 ± 23.40 |
| Change from Baseline at Week 36 | -29.7 ± 26.73 | -27.5 ± 26.28 | -27.8 ± 29.90 | -32.0 ± 26.82 | -26.4 ± 29.86 |
| Change from Baseline at Week 52 | -31.7 ± 27.44 | -29.5 ± 24.66 | -29.4 ± 27.91 | -30.6 ± 28.24 | -32.5 ± 28.17 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of work productivity loss | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 51.3 ± 25.95 | 50.6 ± 25.87 | 54.3 ± 24.85 | 55.8 ± 27.33 |
| Change from Baseline at Week 4 | -14.6 ± 24.59 | -10.2 ± 23.71 | -16.8 ± 26.29 | -10.0 ± 24.06 |
| Change from Baseline at Week 12 | -23.2 ± 28.18 | -22.3 ± 24.34 | -22.8 ± 26.61 | -17.5 ± 28.09 |
| Change from Baseline at Week 24 | -27.1 ± 27.78 | -26.3 ± 27.29 | -23.6 ± 29.40 | -19.3 ± 30.81 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of work productivity loss | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 51.3 ± 25.95 | 50.6 ± 25.87 | 54.3 ± 24.85 | 56.6 ± 27.36 | 57.1 ± 25.14 |
| Change from Baseline at Week 36 | -28.9 ± 27.16 | -25.7 ± 29.54 | -28.6 ± 31.48 | -31.7 ± 30.53 | -26.9 ± 31.02 |
| Change from Baseline at Week 52 | -31.6 ± 29.17 | -28.4 ± 27.11 | -29.3 ± 29.38 | -30.3 ± 30.73 | -32.7 ± 29.65 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of activity impairment | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo |
|---|---|---|---|---|
| Baseline | 61.5 ± 22.74 | 60.5 ± 23.85 | 61.3 ± 21.20 | 62.2 ± 22.11 |
| Change from Baseline at Week 4 | -17.0 ± 22.46 | -14.7 ± 22.07 | -14.8 ± 23.36 | -9.8 ± 20.98 |
| Change from Baseline at Week 12 | -26.5 ± 25.17 | -24.1 ± 24.95 | -22.6 ± 24.93 | -16.9 ± 25.98 |
| Change from Baseline at Week 24 | -30.7 ± 26.20 | -30.4 ± 25.45 | -28.6 ± 24.99 | -21.9 ± 27.78 |
The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.
| percentage of activity impairment | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg |
|---|---|---|---|---|---|
| Baseline | 61.5 ± 22.74 | 60.5 ± 23.85 | 61.3 ± 21.20 | 62.9 ± 21.74 | 59.7 ± 22.10 |
| Change from Baseline at Week 36 | -32.6 ± 26.66 | -31.5 ± 25.66 | -30.2 ± 26.93 | -34.9 ± 26.60 | -27.5 ± 26.14 |
| Change from Baseline at Week 52 | -34.8 ± 26.74 | -33.7 ± 26.44 | -32.9 ± 26.03 | -35.2 ± 28.00 | -30.8 ± 25.99 |
Collected over First dose date up to last dose date (Maximum: 54 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib 200 mg | 3/475 (0.6%) | 35/475 (7.4%) | 128/475 (26.9%) |
| Filgotinib 100 mg | 1/480 (0.2%) | 40/480 (8.3%) | 142/480 (29.6%) |
| Adalimumab | 1/325 (0.3%) | 22/325 (6.8%) | 82/325 (25.2%) |
| Placebo to Filgotinib 200 mg | 1/190 (0.5%) | 7/190 (3.7%) | 36/190 (18.9%) |
| Placebo to Filgotinib 100 mg | 1/191 (0.5%) | 8/191 (4.2%) | 23/191 (12%) |
| Placebo | 2/475 (0.4%) | 21/475 (4.4%) | 61/475 (12.8%) |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg | Placebo |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 4/475 | 4/480 | 3/325 | 1/190 | 0/191 | 1/475 |
| Chest painGeneral disorders | 0/475 | 1/480 | 0/325 | 1/190 | 0/191 | 0/475 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/475 | 0/480 | 0/325 | 1/190 | 0/191 | 0/475 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/475 | 0/480 | 0/325 | 1/190 | 0/191 | 0/475 |
| Ischaemic strokeNervous system disorders | 0/475 | 0/480 | 0/325 | 1/190 | 1/191 | 0/475 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/475 | 0/480 | 0/325 | 1/190 | 0/191 | 0/475 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/475 | 0/480 | 0/325 | 1/190 | 0/191 | 0/475 |
| DermatitisSkin and subcutaneous tissue disorders | 0/475 | 0/480 | 0/325 | 1/190 | 0/191 | 0/475 |
| Deep vein thrombosisVascular disorders | 0/475 | 0/480 | 1/325 | 1/190 | 0/191 | 0/475 |
| Meniere's diseaseEar and labyrinth disorders | 0/475 | 0/480 | 0/325 | 0/190 | 1/191 | 0/475 |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo to Filgotinib 200 mg | Placebo to Filgotinib 100 mg | Placebo |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 41/475 | 49/480 | 21/325 | 8/190 | 6/191 | 14/475 |
| NasopharyngitisInfections and infestations | 43/475 | 48/480 | 24/325 | 7/190 | 6/191 | 25/475 |
| Alanine aminotransferase increasedInvestigations | 17/475 | 25/480 | 21/325 | 7/190 | 3/191 | 11/475 |
| NauseaGastrointestinal disorders | 26/475 | 16/480 | 6/325 | 4/190 | 1/191 | 7/475 |
| Urinary tract infectionInfections and infestations | 18/475 | 19/480 | 17/325 | 10/190 | 8/191 | 6/475 |
| Aspartate aminotransferase increasedInvestigations | 12/475 | 20/480 | 17/325 | 8/190 | 3/191 | 9/475 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 52 ± 12.8 | 53 ± 12.6 | 53 ± 12.9 | 53 ± 12.8 | 53 ± 12.7 |
| Sex: Female, Male(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo | Total |
|---|---|---|---|---|---|
| Female | 379 | 399 | 266 | 391 | 1435 |
| Male | 96 | 81 | 59 | 84 | 320 |
| Race/Ethnicity, Customized(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo | Total |
|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 27 | 27 | 20 | 29 | 103 |
| Race — Asian: Japanese | 40 | 41 | 28 | 38 | 147 |
| Race — Asian: Chinese/Taiwanese/Hong Kong Chinese | 13 | 12 | 8 | 18 | 51 |
| Race — Asian: Korean | 13 | 10 | 4 | 7 | 34 |
| Race — Asian: Other | 56 | 52 | 25 | 46 | 179 |
| Race — Black or African American | 6 | 7 | 10 | 12 | 35 |
| Race — Native Hawaiian or Pacific Islander | 1 | 0 | 0 | 2 | 3 |
| Race — White | 312 | 324 | 229 | 319 | 1184 |
| Race — Other | 7 | 6 | 1 | 3 | 17 |
| Race — Not Permitted | 0 | 1 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 67 | 71 | 54 | 70 | 262 |
| Ethnicity — Not Hispanic or Latino | 404 | 399 | 268 | 400 | 1471 |
| Ethnicity — Not Permitted | 4 | 10 | 3 | 5 | 22 |
| Region of Enrollment(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Adalimumab | Placebo | Total |
|---|---|---|---|---|---|
| United States | 47 | 55 | 37 | 60 | 199 |
| South Africa | 12 | 11 | 3 | 8 | 34 |
| South Korea | 12 | 10 | 4 | 7 | 33 |
| Spain | 14 | 3 | 6 | 7 | 30 |
| Germany | 5 | 6 | 5 | 4 | 20 |
| New Zealand | 5 | 5 | 3 | 5 | 18 |
| United Kingdom | 1 | 2 | 4 | 6 | 13 |
| Canada | 4 | 4 | 3 | 1 | 12 |
| Israel | 4 | 1 | 2 | 4 | 11 |
| Belgium | 2 | 3 | 4 | 1 | 10 |
| Italy | 2 | 1 | 2 | 1 | 6 |
| Netherlands | 0 | 1 | 0 | 1 | 2 |
| Australia | 0 | 1 | 0 | 0 | 1 |
| Ireland | 0 | 1 | 0 | 0 | 1 |
| Poland | 78 | 82 | 64 | 74 | 298 |
| Ukraine | 66 | 73 | 41 | 55 | 235 |
| India | 40 | 39 | 19 | 39 | 137 |
| Russia | 34 | 32 | 22 | 30 | 118 |
| Hungary | 12 | 12 | 5 | 17 | 46 |
| Bulgaria | 7 | 7 | 6 | 14 | 34 |
| Czechia | 7 | 7 | 7 | 13 | 34 |
| Romania | 12 | 6 | 2 | 11 | 31 |
| Serbia | 1 | 7 | 8 | 5 | 21 |
| Slovakia | 2 | 2 | 1 | 3 | 8 |
| Mexico | 33 | 33 | 25 | 34 | 125 |
| Argentina | 15 | 17 | 10 | 15 | 57 |
| Taiwan | 12 | 9 | 7 | 16 | 44 |
| Thailand | 7 | 6 | 6 | 4 | 23 |
| Hong Kong | 1 | 3 | 1 | 2 | 7 |
| Japan | 40 | 41 | 28 | 38 | 147 |
Showing the first 100 of 237 sites across 30 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2016 to primary completion in Jul 2018, 22 months.
Results were first posted in Jan 2021, 2 years 6 months after primary completion. A results delay was requested in Jun 2019.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 22 months is close to that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634